Effects of combinational cyp3a5 6986a>g polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: A meta-analysis

Therapeutic Drug Monitoring

Volumn 36, Issue 4, 2014, Pages 442-447

  Buendia, Jefferson A ^a,b   Bramuglia, Guillermo ^b   Staatz, Christine E ^c  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

CYP3A5; Liver transplant; Pharmacokinetics; Tacrolimus

Indexed keywords

TACROLIMUS; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT;

ALLELE; ARTICLE; CYTOCHROME P450 3A5 GENE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTESTINE; LIVER GRAFT; LIVER TRANSPLANTATION; META ANALYSIS; PRIORITY JOURNAL; ADULT; DONOR; DRUG EFFECTS; FEMALE; GENETICS; GRAFT REJECTION; LIVER; MALE; MIDDLE AGED; SURGERY;

ADULT; ALLELES; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TACROLIMUS; TISSUE DONORS;

EID: 84904547041     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000032     Document Type: Article

References (20)

1. Abbasoglu O. Liver transplantation: yesterday, today and tomorrow. World J Gastroenterol. 2008;14:3117-3122.
2. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004; 43:623.
3. Christians U, Floren LC, Kirchner G, et al. The clinical pharmacokinetics of macrolide immunosuppressants and its impact on the clinical management of organ transplantation. Transplantationsmedizin. 1997;9:75-81.
4. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet. 2010;49: 141-175.
5. de Jonge H, Kuypers DRJ. Pharmacogenetics in solid organ transplantation: current status and future directions. Transplant Rev (Orlando). 2008;22:6-20.
6. Dirks NL, Huth B, Yates CR, et al. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther. 2004;42:701-718.
7. Szekeres T, Haushofer A. Clinical pharmacogenetics of immunosuppresive drugs in organ transplantation. Pharmacogenomics. 2005;6: 163-168.
8. Tang HL, Xie HG, Yao Y, et al. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenet Genomics. 2011;21:713-720.
9. Hozo S, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
10. Provenzani A, Notarbartolo M, Labbozzetta M, et al. The effect of CYP3A5 and ABCBl single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. Ann Transplant. 2009;14:23-31.
11. Barrera-Pulido L, Aguilera-Garcia I, Docobo-Perez F, et al. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. Transplant Proc. 2008;40:2949-2951.
12. Fukudo M, Yano I, Yoshimura A, et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics. 2008;18:413-423.
13. Jun KR, Lee W, Jang MS, et al. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Transplantation. 2009;87:1225-1231.
14. Rahsaz M, Azarpira N, Nikeghbalian S, et al. Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population. Exp Clin Transplant. 2012;10:24-29.
15. Wei-lin W, Jing J, Shu-sen Z, et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl. 2006;12: 775-780.
16. Yu S, Wu L, Jin J, et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation. 2006;81:46-51.
17. Muraki Y, Usui M, Isaji S, et al. Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. Ann Transplant. 2011;16:55-62.
18. Starkel P, Laurent S, Petit M, et al. Early down-regulation of cytochrome P450 3A and 2E1 in the regenerating rat liver is not related to the loss of liver mass or the process of cellular proliferation. Liver. 2000;20: 405-410.
19. Chen SY, Li JL, Meng FH, et al. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism-a prospective, randomized, controlled study. Clin Transplant. 2013;2013:12101.
20. Ji E, Choi L, Suh KS, et al. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. Transplantation. 2012;94(8):866-872.